Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1275532

registered interest
date	12/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	What plans he has to train healthcare professionals in communicating the (a) safety and (b) effectiveness of covid-19 vaccines.
tabling member constituency	City of Durham
tabling member printed	Mary Kelly Foy
uin	910622
answer	answer is ministerial correction date of answer 12/01/2021 answer text <p>We offer our thanks to all healthcare professionals for their exceptional work on the front line administering vaccines to those who are most vulnerable.</p><p>Safety is absolutely paramount in any vaccination programme. Public Health England have produced comprehensive training and information materials for COVID-19 vaccinators. These include information about the safety and effectiveness of COVID-19 vaccines, as well as key messages for healthcare professionals to convey to those being vaccinated.</p><p>All vaccinating staff involved in the deployment programme must complete training that includes modules on the safety and effectiveness of vaccines. Communicating about the safety and effectiveness of the vaccine is also a component of the process for gaining informed consent.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/01/2021 16:13:24 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4753 label Biography information for Mary Kelly Foy

1275535

registered interest
date	12/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	What progress he has made on the (a) administration and (b) distribution of covid-19 vaccines.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	910630
answer	answer is ministerial correction date of answer 12/01/2021 answer text <p>We are delighted that over 2.2 million of the most vulnerable people in the country have now received the first dose of their COVID-19 vaccine.</p><p>We are on track to deliver our commitment of offering a first vaccine to everyone in the most vulnerable groups by the middle of next month.</p><p>There are already more than 2,700 sites across the United Kingdom already offering vaccines to those at risk by age and clinical priority.</p><p>As set out in the comprehensive UK vaccines delivery plan, by the end of January, everyone in England will be within 10 miles of a vaccination site, or, for a small number of highly rural areas, the vaccine will be brought to them via mobile teams.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/01/2021 16:15:11 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4783 label Biography information for Kate Osborne

1274717

registered interest
date	08/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the Pfizer/BioNTech covid-19 vaccine if the second dose is administered 12 weeks after the first dose.
tabling member constituency	Manchester, Gorton
tabling member printed	Afzal Khan
uin	134547
answer	answer is ministerial correction date of answer 18/01/2021 answer text <p>A recent study demonstrated a two-dose vaccine efficacy of 95% for the Pfizer/Biotech COVID-19 vaccine, with a second dose delivered between 19 and 42 days. The Joint Committee on Vaccination and Immunisation (JCVI) has reviewed evidence on the Pfizer/BioNTech COVID-19 vaccine and advised an interval of up to 12 weeks between doses. The considerations of the JCVI on extended intervals has been published, and is available here: <a href="https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement" target="_blank">https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement</a></p><p>Using data available from clinical trials, Public Health England estimated that vaccine efficacy from the first dose of the Pfizer/BioNTech vaccine is approximately 89%. This is the efficacy calculated 15 to 21 days after the first dose. The estimate for 15 to 28 days is 91% which includes seven days after the second dose, but is prior to the time protection that may be expected from the second dose. There is no estimate of efficacy for a single dose beyond 21 days, but the JCVI’s view is that protective immunity from the first dose likely lasts for a duration of 12 weeks.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 134548 134549 question first answered 18/01/2021 11:48:46 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 73470 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4671 label Biography information for Afzal Khan

1274718

registered interest
date	08/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the Pfizer/BioNTech covid-19 vaccine if the second dose is administered three weeks after the first dose.
tabling member constituency	Manchester, Gorton
tabling member printed	Afzal Khan
uin	134548
answer	answer is ministerial correction date of answer 18/01/2021 answer text <p>A recent study demonstrated a two-dose vaccine efficacy of 95% for the Pfizer/Biotech COVID-19 vaccine, with a second dose delivered between 19 and 42 days. The Joint Committee on Vaccination and Immunisation (JCVI) has reviewed evidence on the Pfizer/BioNTech COVID-19 vaccine and advised an interval of up to 12 weeks between doses. The considerations of the JCVI on extended intervals has been published, and is available here: <a href="https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement" target="_blank">https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement</a></p><p>Using data available from clinical trials, Public Health England estimated that vaccine efficacy from the first dose of the Pfizer/BioNTech vaccine is approximately 89%. This is the efficacy calculated 15 to 21 days after the first dose. The estimate for 15 to 28 days is 91% which includes seven days after the second dose, but is prior to the time protection that may be expected from the second dose. There is no estimate of efficacy for a single dose beyond 21 days, but the JCVI’s view is that protective immunity from the first dose likely lasts for a duration of 12 weeks.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 134547 134549 question first answered 18/01/2021 11:48:46 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 73466 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4671 label Biography information for Afzal Khan

1274719

registered interest
date	08/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the evidence for the decision to administer the second dose of the Pfizer/BioNTech covid-19 vaccine 12 weeks after the first dose.
tabling member constituency	Manchester, Gorton
tabling member printed	Afzal Khan
uin	134549
answer	answer is ministerial correction date of answer 18/01/2021 answer text <p>A recent study demonstrated a two-dose vaccine efficacy of 95% for the Pfizer/Biotech COVID-19 vaccine, with a second dose delivered between 19 and 42 days. The Joint Committee on Vaccination and Immunisation (JCVI) has reviewed evidence on the Pfizer/BioNTech COVID-19 vaccine and advised an interval of up to 12 weeks between doses. The considerations of the JCVI on extended intervals has been published, and is available here: <a href="https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement" target="_blank">https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement</a></p><p>Using data available from clinical trials, Public Health England estimated that vaccine efficacy from the first dose of the Pfizer/BioNTech vaccine is approximately 89%. This is the efficacy calculated 15 to 21 days after the first dose. The estimate for 15 to 28 days is 91% which includes seven days after the second dose, but is prior to the time protection that may be expected from the second dose. There is no estimate of efficacy for a single dose beyond 21 days, but the JCVI’s view is that protective immunity from the first dose likely lasts for a duration of 12 weeks.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 134547 134548 question first answered 18/01/2021 11:48:45 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 73464 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4671 label Biography information for Afzal Khan

1274784

registered interest
date	08/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Leicestershire
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to support community pharmacies in Leicestershire with the roll-out of covid-19 vaccinations.
tabling member constituency	Bosworth
tabling member printed	Dr Luke Evans
uin	134604
answer	answer is ministerial correction date of answer 18/01/2021 answer text <p>Community pharmacies providing the COVID-19 vaccination, regardless of their location in England, will be eligible for support in the form of training, funding for the service including fee per vaccination, additional venue hire costs and pre-agreed one off set up costs and non-monetary support - for example, access to vaccines, consumables, personal protective equipment and other equipment to operate the site.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 18/01/2021 09:18:21 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4781 label Biography information for Dr Luke Evans

1273801

registered interest
date	06/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what the existing weekly capacity for vaccine production is in the UK.
tabling member constituency	Warley
tabling member printed	John Spellar
uin	133636
answer	answer is ministerial correction date of answer 15/01/2021 answer text <p>The UK has a strong manufacturing basis in vaccines and life sciences, with a range of sites around the country.</p><p> </p><p>Through the Vaccine Taskforce, the Government has entered commercial arrangements with a number of these sites to manufacture and fill-finish COVID-19 vaccines. The Government has also invested over £230 million in expanding the UK’s vaccine manufacturing base, through several investments, such as the Vaccines Manufacturing and Innovation Centre and Cell and Gene Manufacturing and Innovation Centre.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/01/2021 14:14:44 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	318 label Biography information for John Spellar

1273936

registered interest
date	06/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Clothing and Textiles: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans his Department has to support the UK's fashion and textile industry to rebuild following the covid-19 outbreak.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	133903
answer	answer is ministerial correction date of answer 15/01/2021 answer text <p>The Government continues to offer a comprehensive support package for businesses including loan schemes, grant funding, tax deferrals, the Self-Employment Income Support Scheme and the Coronavirus Job Retention Scheme, all of which have been designed to be accessible to businesses in most sectors and across the UK.</p><p>On 5 January, my Rt. Hon. Friend Mr Chancellor of the Exchequer announced a £594 million discretionary fund to support other impacted businesses outside of the retail, hospitality, and leisure sectors, which is in addition to £1.1 billion further discretionary grant funding for Local Authorities and Local Restriction Support Grants worth up to £3,000 a month.</p><p>Ministers and officials in the Department and across Government continue to regularly engage with the fashion and textiles industry to explore ways in which Government can support long term recovery in the sector.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/01/2021 11:30:22 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4412 label Biography information for Dr Lisa Cameron

1274116

registered interest
date	06/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what protocols his Department has put in place to minimise the risk of disruption in the supply chain for the distribution of the covid-19 vaccine.
tabling member constituency	Wakefield
tabling member printed	Imran Ahmad Khan
uin	134252
answer	answer is ministerial correction date of answer 12/01/2021 answer text <p>Public Health England (PHE) has worked with its specialist medical logistics partners over many months to plan for the storage and distribution of COVID-19 vaccines across the United Kingdom.</p><p>PHE has well established ordering and distribution mechanisms which have been built over many years of successful delivery of vaccines for the national immunisation programme. These have been enhanced to accommodate for the challenging storage temperatures for some of the COVID-19 vaccines. This has been in combination with an increased level of service for all UK locations and flexibility to manage urgent delivery requirements.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/01/2021 16:44:03 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4841 label Biography information for Imran Ahmad Khan

1274157

registered interest
date	06/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of including teachers on the priority covid-19 vaccine list.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133828
answer	answer is ministerial correction date of answer 18/01/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) consists of independent experts who advise the Government on which vaccines the United Kingdom should use and provide advice on prioritisation at a population level.  For the first phase, the JCVI has advised that the vaccine be given to care home residents and staff, as well as frontline health and social care workers, then to the rest of the population in order of age and clinical risk factors.</p><p>If teachers are captured in phase one due to their age or clinical risk factors then they will be prioritised. However, as advised by the JCVI, we are not considering vaccinating teachers in phase one. Prioritisation decisions for the next phase of delivery are subject to the surveillance and monitoring of data and information from phase one, as well as further input from independent scientific experts such as the JCVI. Phase two of the deployment may include further reduction in hospitalisation and targeted vaccination of those at high risk of exposure and/or those delivering key public services, such as teachers.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 18/01/2021 11:57:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4079 label Biography information for Julian Sturdy